Clinical trials · Texas
B Cell Malignancies clinical trials in Texas
We’re tracking 95 recruiting b cell malignancies studies with a site in Texas — including Early Phase 1, Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Texas
- NCT05006716RecruitingPhase 1/Phase 2
Testing a new drug for certain B-cell blood cancers
This Phase 1/2 trial studies the safest dose and then effectiveness of BGB-16673 in people with specific B-cell malignancies. It may help by targeting cancer cells in these blood cancers, especially after other treatments like BTK inhibitors.
Houston, TexasAges 18 years+ - NCT06533579RecruitingPhase 1/Phase 2
Gene therapy for CD19-positive blood cancers
This trial tests a new gene therapy treatment for people with certain types of leukemia or lymphoma that have the CD19 marker and have not responded to other treatments. The therapy uses a virus to deliver a gene to target and kill cancer cells.
Houston, TexasAges 13–90 - NCT04745949RecruitingPhase 2
Testing first-line antibody plus immunotherapy for mediastinal lymphoma
This trial tests a combination of antibody therapy and immunotherapy (plus standard chemo) as first treatment for primary mediastinal large B-cell lymphoma. It may help shrink the lymphoma and improve how long patients stay in remission.
Houston, TexasAges 18 years+ - NCT05886036RecruitingPhase 2
Comparing rituximab vs mosunetuzumab for NLPHL
This trial compares two immunotherapy drugs, rituximab and mosunetuzumab, to see which works better for people with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) who need treatment. It's for both newly diagnosed and previously treated patients.
Houston, TexasAges 18 years+ - NCT06590961RecruitingPhase 1
A new drug (UBX-303061) for B-cell cancers that came back or didn't respond
A trial testing an experimental drug (UBX-303061) for people with certain B-cell blood cancers (like CLL, DLBCL, or MCL) that have returned or not responded to at least two other treatments. The goal is to see if the drug is safe and works when other options are no longer available.
Houston, TexasAges 18 years+ - NCT03866382RecruitingPhase 2
Immunotherapy plus a targeted drug for rare genitourinary tumors
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
Bryan, TexasAges 18 years+ - NCT07188558RecruitingPhase 3
Comparing ronde-cel to standard CAR T-cell therapy for large B-cell lymphoma
This trial tests a new treatment called ronde-cel against the usual CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded to initial treatment. The goal is to see if ronde-cel works better.
Austin, TexasAges 18 years+ - NCT06542250RecruitingPhase 1/Phase 2
Study of a new immune therapy for relapsed B-cell cancers
This trial tests a new drug (AZD5492) that helps your immune system attack a protein (CD20) on cancer cells. It's for people with B-cell cancers that have come back after at least 2 prior treatments.
Houston, TexasAges 18 years+ - NCT06564038RecruitingPhase 1/Phase 2
Study of AZD0486 alone or with other drugs for B-cell cancers
This trial tests a new drug called AZD0486, alone or with other medicines, for people with certain types of B-cell cancers that have come back or not responded to treatment. The goal is to see how safe and effective it is.
Houston, TexasAges 18 years+ - NCT04139304RecruitingEarly Phase 1
Study of daratumumab with EPOCH for plasmablastic lymphoma
This early-phase trial tests daratumumab combined with a dose-adjusted chemotherapy plan (EPOCH) to treat plasmablastic lymphoma. It aims to improve how well the cancer responds, including in people living with HIV or without HIV.
Houston, TexasAges 18 years+ - NCT04830137RecruitingPhase 1
Test drug NX-2127 for hard-to-treat B-cell blood cancers
This Phase 1 trial tests the safety and early effectiveness of NX-2127 in adults with relapsed or refractory B-cell cancers. If you qualify, you may receive a new targeted treatment because your cancer has returned or not responded to prior therapies.
Houston, TexasAges 18 years+ - NCT04792489RecruitingPhase 2
CAR-T cell therapy for aggressive B-cell lymphomas
This trial tests a new CAR-T cell treatment (MB-CART2019.1) for people with certain types of aggressive B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to prior treatments. It aims to see if this therapy can help when other options have failed.
Dallas, TexasAges 18 years+ - NCT05131022RecruitingPhase 1
Study of NX-5948 for relapsed B-cell blood cancers
This Phase 1 study tests NX-5948 in adults whose B-cell cancers have come back or did not respond to prior treatment. It aims to find a safe dose and see how well the treatment works in different types of B-cell malignancies.
Houston, TexasAges 18 years+ - NCT05544019RecruitingPhase 1
Testing an investigational drug for mature B-cell cancers
This early (Phase 1) study tests SGR-1505, an experimental treatment, in people with certain mature B-cell cancers. It’s mainly designed to see how the drug works in the body and to check safety, and it may offer an option if standard treatments aren’t enough.
Dallas, TexasAges 18 years+ - NCT05615636RecruitingPhase 2
Study of four medicines for relapsed B-cell lymphoma
This Phase 2 trial tests a combination of several medicines for people whose lymphoma has come back or did not respond to prior treatment. It aims to shrink the lymphoma by using different ways to attack B-cell cancer.
Houston, TexasAges 18 years+ - NCT05643742RecruitingPhase 1/Phase 2
Study of CTX112 for B-cell cancers that came back or did not respond
This Phase 1/2 study tests how safe and effective CTX112 is for adults whose B-cell cancer has returned or is not responding to treatment. It aims to see whether CTX112 can control the cancer while monitoring side effects closely.
San Antonio, TexasAges 18 years+ - NCT05780034RecruitingPhase 1
Study drug AC676 for certain relapsed blood cancers
This Phase 1 trial tests AC676, a study medicine, for adults with certain B-cell blood cancers that have come back or did not respond to prior treatment. It may help people who have tried standard therapies and need new options.
Dallas, TexasAges 18 years+ - NCT05890352RecruitingPhase 2
Add new medicines to standard treatment for returning lymphoma
This Phase 2 study tests whether adding tafasitamab, lenalidomide, tazemetostat, and zanubrutinib (along with standard lymphoma treatment) can improve outcomes in people whose large B-cell lymphoma has returned or not responded. It may help control disease more effectively and improve response duration for eligible patients.
San Antonio, TexasAges 18 years+ - NCT06131801Recruiting
Crushed venetoclax tablet solution study for blood cancers
This study checks how the body handles venetoclax when it's given as a liquid made from crushed tablets. It's for children and young adults with blood cancers who already take venetoclax crushed or through a feeding tube.
Houston, TexasAges birth–38 years - NCT07101328RecruitingPhase 1
Study of LY4152199 for Lymphoma That Returned or Didn't Respond
This study tests a new medicine called LY4152199 for people with certain types of lymphoma (follicular or diffuse large B-cell) that came back or didn't respond to previous treatment. The goal is to see if the drug is safe and how well it works.
Dallas, TexasAges 18 years+ - NCT06343311RecruitingPhase 1/Phase 2
T-cell therapy for adults with relapsed or refractory B-cell lymphoma
This trial tests a new T-cell therapy (EB103) for people with B-cell non-Hodgkin's lymphoma that has come back or stopped responding to treatment. It aims to see if the therapy is safe and effective.
Dallas, TexasAges 18 years+ - NCT06634589RecruitingPhase 1/Phase 2
Study of a new drug combo for returning B-cell blood cancers
This trial tests a new drug combination for people with B-cell blood cancers (like lymphoma or leukemia) that have returned or stopped responding to treatment. It aims to find out if the combination is safe and works better than current options.
Houston, TexasAges 18 years+ - NCT07271667RecruitingPhase 2
Study of emavusertib with zanubrutinib for CLL and other B-cell cancers
This trial combines an experimental drug, emavusertib, with zanubrutinib (a standard targeted therapy) for people with chronic lymphocytic leukemia (CLL) or other B-cell cancers. It aims to see if the combination can improve response in patients who still have some disease despite taking zanubrutinib or whose disease has worsened on it.
Dallas, TexasAges 18 years+ - NCT07283679RecruitingPhase 1/Phase 2
NK cell therapy with two immune agents for returning lymphoma
This trial tests a new combination of specially grown immune cells (NK cells) plus two drugs that help them attack cancer. It's for people with a type of B-cell lymphoma that came back after at least two prior treatments or a stem cell transplant, and who have either failed or are not eligible for CAR-T cell therapy.
Houston, TexasAges 18 years+
B Cell Malignancies trials by city in Texas
Where these studies are running in Texas
Institutions with a site for the recruiting b cell malignancies studies listed above.
- The University of Texas MD Anderson Cancer Center · 14 studies
- University of Texas Southwestern Medical Center · 6 studies
- Research Site · 2 studies
- Texas Transplant Institute · 2 studies
- Baylor College of Medicine
- Baylor Scott & White Research Institute
- Baylor University Medical Center
- Ben Taub General Hospital
What taking part in a b cell malignancies study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
B Cell Malignancies trials in other states
Common questions
- Are there b cell malignancies clinical trials in Texas?
- Yes. We're currently tracking 95 recruiting b cell malignancies studies with a site in Texas, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a b cell malignancies study in Texas?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Texas to take part?
- Not necessarily. These studies have a site in Texas, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a b cell malignancies trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New b cell malignancies studies open in Texas regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.